A record of what Deven Choksey said publicly, with the source. Not advice.
“Bullish on Glenmark Pharmaceuticals with a 'Buy' call and a target price of ₹1,894 apiece for October. The firm expects revenue to grow at 10.0% CAGR and Adj. PAT at 42.5% CAGR over FY23-FY26E, assigning a PE multiple of 31.0x on FY26E EPS.”
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹1,894, as stated.
Window: 12 months, the default when no time frame is stated.
Window still open: no verdict until a close reaches a level or the window ends.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.